Scott Daniel Cormack
Director/Board Member at PC-TRiADD
Profile
Scott Daniel Cormack is the founder of three companies.
OncoGenex Technologies, Inc. was founded in 2000, For Tomorrow was founded in 1999, and OncoGenex Pharmaceuticals, Inc. was founded in 1991.
At OncoGenex Technologies, Inc., he held the title of President & Chief Executive Officer from 2000 to 2008.
At OncoGenex Pharmaceuticals, Inc., he held the title of President, CEO, Secretary, Treasurer & Director from 2014 to 2017.
At For Tomorrow, he held the title of President in 1999.
Currently, he holds positions as Director-Prostate Centre at Vancouver General Hospital, Director at PC-TRiADD, and Director at Novelogics Biotechnology, Inc. He previously held positions as Chairman, President & Chief Executive Officer at Salpep Biotechnology, Inc. from 2000 to 2001, Director at LifeSciences British Columbia in 2008, Director at Fe Pharmaceuticals (Canada), Inc., Director at Aurinia Pharmaceuticals, Inc. from 2012 to 2014, Director at Achieve Life Sciences, Inc. from 2008 to 2021, Chief Operating Officer at NeuroSpheres Ltd.
from 1995 to 1998, Vice President at Milestone Medica Corp.
from 1998 to 2001, and Manager-Technology Immunomodulators at Vetrepharm, Inc. from 1986 to 1991.
He received his undergraduate degree from the University of Alberta in 1986.
Scott Daniel Cormack active positions
| Companies | Position | Start |
|---|---|---|
PC-TRiADD
 PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | Director/Board Member | - |
| Vancouver General Hospital | Corporate Officer/Principal | - |
Novelogics Biotechnology, Inc.
 Novelogics Biotechnology, Inc. BiotechnologyHealth Technology Novelogics Biotechnology, Inc. is a pre-clinical stage biotech company based in Vancouver, Canada, that is developing innovative antibody immunotherapies for cancer using a novel "interceptor" approach. Novelogics aims to revolutionize cancer treatment with its innovative solution that acts as an "interceptor" of unattached immunosuppressive proteins that have the capacity to shut down critical cancer-killing immune cells. The Canadian company is seeking staged investments and/or partnerships to advance its program. The company was founded by Wayne Cheney and Elaine Allison, with Allison serving as CEO since incorporation. | Director/Board Member | - |
Former positions of Scott Daniel Cormack
| Companies | Position | End |
|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. | Director/Board Member | 2021-05-10 |
OncoGenex Pharmaceuticals, Inc.
 OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | Chief Executive Officer | 2017-07-31 |
| AURINIA PHARMACEUTICALS INC. | Director/Board Member | 2013-12-31 |
LifeSciences British Columbia
 LifeSciences British Columbia BiotechnologyHealth Technology LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada. | Director/Board Member | 2008-10-01 |
OncoGenex Technologies, Inc.
 OncoGenex Technologies, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Technologies, Inc. develops drugs for cancer patients. Its products are being developed to block the production of specific proteins associated with the development of treatment resistance which will increase survival time and improve the quality of life for cancer patients. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Chief Executive Officer | 2008-08-21 |
Training of Scott Daniel Cormack
| University of Alberta | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ACHIEVE LIFE SCIENCES, INC. | Health Technology |
| AURINIA PHARMACEUTICALS INC. | Health Technology |
| Private companies | 12 |
|---|---|
OncoGenex Technologies, Inc.
OncoGenex Technologies, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Technologies, Inc. develops drugs for cancer patients. Its products are being developed to block the production of specific proteins associated with the development of treatment resistance which will increase survival time and improve the quality of life for cancer patients. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Health Technology |
| Milestone Medica Corp. | Finance |
| NeuroSpheres Ltd. | |
LifeSciences British Columbia
LifeSciences British Columbia BiotechnologyHealth Technology LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada. | Health Technology |
| Salpep Biotechnology, Inc. | |
| Vetrepharm, Inc. | |
| For Tomorrow | |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | Health Technology |
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | Commercial Services |
| Vancouver General Hospital | |
Fe Pharmaceuticals (Canada), Inc.
 Fe Pharmaceuticals (Canada), Inc. Pharmaceuticals: MajorHealth Technology Fe Pharmaceuticals (Canada), Inc. operates as a research institution. It offers indication & treatment challenge, technical innovation and market services. The company was founded by William M. Cheliak and Bruce Holbein and is headquartered in Halifax, Canada. | Health Technology |
Novelogics Biotechnology, Inc.
Novelogics Biotechnology, Inc. BiotechnologyHealth Technology Novelogics Biotechnology, Inc. is a pre-clinical stage biotech company based in Vancouver, Canada, that is developing innovative antibody immunotherapies for cancer using a novel "interceptor" approach. Novelogics aims to revolutionize cancer treatment with its innovative solution that acts as an "interceptor" of unattached immunosuppressive proteins that have the capacity to shut down critical cancer-killing immune cells. The Canadian company is seeking staged investments and/or partnerships to advance its program. The company was founded by Wayne Cheney and Elaine Allison, with Allison serving as CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Scott Daniel Cormack
